The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.
D001794:Blood Pressure / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D010879:Piperazines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D010919:Placebos; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D012016:Reference Values; D012119:Respiration / Q000187:drug effects
D018696:Neuroprotective Agents; D010879:Piperazines; D010919:Placebos; D011743:Pyrimidines; C081980:sipatrigine